NPC Letter to FDA (13th August 2021)

The INPDA is committed to improving outcomes for the global Niemann-Pick community and to ensuring equitable access to safe and effective therapies.  In support of the US patient community and in recognition of the global impact of FDA decision making, the INPDA has joined forces with NNPDF and the APMRF to respond to the Listening Session held on August 3. A Summary Report of the Listening Session will be available soon.